Navigation Links
Regado Biosciences, Inc. Announces Presentation of the Results of the RADAR Phase 2b Clinical Trial of Its Anticoagulant System REG1 at the i2 Summit During the American College of Cardiology 2011 60th Annual Scientific Session & Expo in New Orleans
Date:3/28/2011

pecific GPVI inhibitor and its active control agent (RB571 and RB515, respectively).  REG3 is planned to enter phase 1 human clinical testing in 2011 and will be indicated for antiplatelet therapy.  Information pertaining to Regado's clinical programs may be obtained at www.clinicaltrials.gov.

ABOUT APTAMERS

Pegnivacogin is a member of a class of compounds called aptamers.  Aptamers are single stranded oligonucleotides that adopt a specific conformation enabling direct, specific inhibition of the targeted protein.   A key unique feature of aptamers derives from the fact that they are formed from nucleic acids.  As such, their pharmacologic activity can be controlled by a matched, complementary oligonucleotide active control agent (the Watson-Crick base pair complement of a fraction of the agent to be controlled), which can bind to the aptamer, removing it from its target and reversing its biologic effects.  Anivamersen is the complementary active control agent of pegnivacogin.  

More information can be found at www.regadobio.com

Contact:  Ellen McDonald, Chief Business Officer, Regado Biosciences
1-908-580-2113, emcdonald@regadobio.com

Media Contact:
Tiberend Strategic Advisors, Inc.
1-212-827-0020
Andrew Mielach, amielach@tiberend.com
or
Farrell Denby, fdenby@tiberend.com


'/>"/>
SOURCE Regado Biosciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Regado Biosciences to Present at the 2011 RBC Capital Markets Healthcare Conference in New York City
2. Regado Biosciences, Inc. Introduces REG3, a Novel Aptamer-Based Inhibitor of Glycoprotein VI and its Matched Active Control Agent, at the American Heart Association (AHA) Scientific Sessions 2010 Meeting
3. Regado Biosciences, Inc. Presents Pharmacokinetic and Pharmacodynamic (PK/PD) Substudy Results From its Phase 2b RADAR Trial at the American Heart Association (AHA) Scientific Sessions 2010 Meeting
4. Regado Biosciences, Inc. Presents Two Abstracts on the Subcutaneous Depot Formulation of Pegnivacogin, a Nuclease-Stabilized RNA Aptamer, Direct Factor IXa Inhibitor and Part of the REG2 Anticoagulant System, at the American Heart Association (AHA)
5. Regado Biosciences to Present at the IMPACT 2010 Conference in Philadelphia, Pennsylvania
6. Regado Biosciences, Inc. Presents the First-In-Human Clinical Experience with REG2 at the American College of Chest Physicians (ACCP) Coagulation and Heart Disease Sessions in Vancouver, BC, Canada on November 2, 2010
7. Regado Biosciences to Present at the Stifel Nicolaus Healthcare Conference 2010 on September 16, 2010 in Boston, Massachusetts
8. Regado Biosciences to Present at the 2010 Wells Fargo Healthcare Conference on June 24, 2010 in Boston, Massachusetts
9. Regado Biosciences, Inc. Introduces REG2, Its Second Product Candidate, at the American College of Cardiology Conference, 59th Annual Scientific Session, in Atlanta, Georgia on March 15, 2010
10. Regado Biosciences to Present at the Piper Jaffray 21st Annual Health Care Conference on December 1, 2009
11. Regado Biosciences to Present at the Ninth Annual Joint Symposium of BioNJ and Pennsylvania Bio on November 17, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... Mettler-Toledo International Inc. (NYSE: MTD ) ... are the highlights: , Sales in local ... prior year. Reported sales decreased 4% as currency reduced ... Net earnings per diluted share as reported (EPS) were ... EPS was $2.80 , an increase of 9% ...
(Date:7/30/2015)... July 30, 2015  EP Global Communications, Inc. (Public ... recently contacted the Company about discussing EPGL,s electronic ... as Monday, August 3, 2015.  Novartis CEO ... that the coming electronic contact lens market could ... the next several years.  Novartis partnered with Google ...
(Date:7/30/2015)... PTC Therapeutics, Inc. (NASDAQ: PTCT ) ... for the second quarter ending June 30, 2015. ... the organization.  We are excited to be near the ... ever conducted with topline results expected in the fourth ... PTC Therapeutics, Inc. "Translarna is now commercially available in ...
Breaking Medicine Technology:Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 2Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 3Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 4Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 5Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 6Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 7Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 8Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 9Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 10Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 11Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 12Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 13Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 14PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 2PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 3PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 4PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 5PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 6PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 7PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 8PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 9PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 10
... Biosciences, a segment of BD (Becton, Dickinson and Company) (NYSE: ... Cytometer, a flexible, reliable and scalable system that can analyze ... research applications.   “We engineered cutting-edge innovation ... three foundations in mind,” said James Glasscock, President of Cell ...
... 2011 Ann Arbor SPARK recently celebrated the conclusion of ... a reception.  At the Ann Arbor SPARK Boot Camp Celebration, ... Camp" winner, based on the quality of its investor pitch ... though the Ann Arbor SPARK Business Accelerator.   ...
Cached Medicine Technology:BD Biosciences Launches New Cell Analyzer to Streamline Research Workflow 2BD Biosciences Launches New Cell Analyzer to Streamline Research Workflow 3Brio Device Awarded Best of Ann Arbor SPARK's Boot Camp 2
(Date:7/31/2015)... ... July 31, 2015 , ... Indosoft, Inc., is pleased to announce a ... Q-Suite is their flagship contact center ACD system for Asterisk-based call centers . ... shows the script components to the agent only when wanted, and allows for validation ...
(Date:7/31/2015)... Minneapolis, Minn. (PRWEB) , ... July 31, 2015 ... ... software, is selected as a contributor for LeadingAge’s Center for Aging Services Technologies ... studies designed to help long-term and post-acute care providers understand the benefits of ...
(Date:7/31/2015)... ... July 31, 2015 , ... The ... Karmanos Center for Natural Birth . The Karmanos Center for Natural Birth ... childbirth experience. With nurses and caregivers that are trained in holistic birth approaches, ...
(Date:7/31/2015)... OR (PRWEB) , ... July 31, 2015 , ... New ... Granary District Stage Amphitheater in McMinnville, Oregon August 15th, 2015 from 9am – 12pm. ... an exciting and important day for the entire community as the culmination of months ...
(Date:7/31/2015)... ... July 31, 2015 , ... An ... from NBC talked about a woman’s unfortunate experience having cosmetic skin procedures done ... face, which resulted in blistering, swelling, bruising, and pain. This woman’s experience is ...
Breaking Medicine News(10 mins):Health News:Q-Suite 5.9 Adds Validation Tools to Call Center Software Agent Screen 2Health News:LeadingAge Selects Eldermark Case Study to Highlight Medication Error Reduction Results 2Health News:LeadingAge Selects Eldermark Case Study to Highlight Medication Error Reduction Results 3Health News:Timber Frame Raising: Granary District Stage Amphitheater Timber Frame Hand-Raising by New Energy Works Timberframers 2Health News:Timber Frame Raising: Granary District Stage Amphitheater Timber Frame Hand-Raising by New Energy Works Timberframers 3Health News:Dermatologists Discuss Rise in Unqualified Practitioners of Cosmetic Dermatology 2Health News:Dermatologists Discuss Rise in Unqualified Practitioners of Cosmetic Dermatology 3
... 2012)When combined with other treatments, the drug cetuximabwhich works ... been shown to extend survival in certain types of ... percent of colorectal cancer patientsspecifically those who carry a ... to the drug. Researchers at Fox Chase Cancer ...
... the next generation of global health scientists, Fogarty International ... Health are building a network of U.S. academic institutions ... a significant mentored research experience in a developing country. ... over the next five years to support 400 early-career ...
... autoimmune diseases also display a tendency to develop atherosclerosis ... arteries. Clinical researchers at LMU, in collaboration with colleagues ... to explain the connection between the two types of ... of immune cells called plasmacytoid dendritic cells (pDCs). pDCs ...
... ,People with metal-on-metal hip replacements do not have an increased ... receive the device, according to a new study. However, ... Universities of Bristol and Exeter in the U.K. report. ... and Wales, which contains records on more than 1 million ...
... News) -- A new study finds that preteen girls ... experience side effects after receiving the human papillomavirus (HPV) vaccine, ... are similar to those associated with other vaccines. U.S. ... to 26, within two weeks after they received the Gardasil ...
... April 3 (HealthDay News) -- Adding the drug cetuximab (brand ... colon cancer did not improve disease-free survival in patients, a ... who undergo surgery have a 50 percent chance of cure, ... leucovorin, fluorouracil and oxaliplatin (a regimen known as FOLFOX) after ...
Cached Medicine News:Health News:Researchers uncover a viable way for colorectal cancer patients to overcome drug resistance 2Health News:NIH awards $20 million over 5 years to train next generation of global health researchers 2Health News:NIH awards $20 million over 5 years to train next generation of global health researchers 3Health News:The long arm of the dendritic cell 2Health News:The long arm of the dendritic cell 3Health News:No Added Cancer Risk From Hip Replacement Materials: Study 2Health News:Preteens More Likely to Report HPV Vaccine Side Effects 2Health News:Experimental Chemo Combo for Colon Cancer Disappoints 2
... tasks and delivers consistently reliable ... and ensure testing accuracy in ... automated reticulocyte counts and three-dimensional ... sensitivity, specificity and efficiency in ...
... staff scheduling solution that streamlines and ... the synchronization and interface of workforce ... maintains staff schedules and replacements; tracks ... shift and work location schedules; and ...
... A first of its kind product, ... most appealing colors and state-of-the-art SPECT technology ... cardiology system. The exclusive, contoured patient chair ... cardiac scanning. A relaxed patient moves ...
... Series of Cryoablation Catheters combines the safeguard ... the two-stage cooling system of the CryoCor ... of cryoenergy to the ablation site. CryoCor's ... create the transmural lesions necessary to permanently ...
Medicine Products: